Personalis (NASDAQ:PSNL) Reaches New 1-Year High – Should You Buy?

Shares of Personalis, Inc. (NASDAQ:PSNL) reached a new 52-week high during trading on Thursday . The company traded as high as $17.04 and last traded at $16.4580, with a volume of 2215499 shares trading hands. The stock had previously closed at $15.81.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Friday, July 17th. Zacks Research cut shares of Personalis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 21st. BTIG Research raised their price target on shares of Personalis from $11.00 to $16.25 and gave the company a “buy” rating in a report on Monday, July 20th. Lake Street Capital lowered shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price target for the company. in a research report on Monday, July 20th. Finally, Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $14.25.

Personalis Stock Performance

The stock has a market cap of $1.92 billion, a PE ratio of -16.86 and a beta of 2.27. The company’s 50-day moving average price is $13.30 and its two-hundred day moving average price is $9.68.

Personalis (NASDAQ:PSNL) last announced its earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The company had revenue of $22.36 million during the quarter, compared to analysts’ expectations of $16.69 million. Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%. Equities research analysts forecast that Personalis, Inc. will post -1.07 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Christopher M. Hall sold 100,000 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the transaction, the chief executive officer directly owned 235,986 shares in the company, valued at approximately $3,558,668.88. This represents a 29.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $14.00, for a total value of $69,748.00. Following the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at approximately $2,783,662. This represents a 2.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 435,032 shares of company stock valued at $5,599,929. Corporate insiders own 4.20% of the company’s stock.

Institutional Trading of Personalis

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada grew its position in Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after acquiring an additional 2,395 shares during the last quarter. Dynamic Technology Lab Private Ltd lifted its holdings in shares of Personalis by 75.6% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock worth $269,000 after acquiring an additional 33,044 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Personalis by 55.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock valued at $998,000 after purchasing an additional 101,706 shares in the last quarter. Focus Partners Wealth purchased a new stake in shares of Personalis in the 1st quarter valued at $47,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of Personalis by 505.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock valued at $193,000 after purchasing an additional 24,621 shares in the last quarter. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.